BioCardia reports CardiAMP trial improves exercise tolerance in chronic myocardial ischemia patients

• BioCardia reported results already presented at EuroPCR from the preliminary open-label cohort of its CardiAMP chronic myocardial ischemia trial.
• The update showed the minimally invasive cell-therapy procedure was well tolerated, with no major safety issues reported.
• Patients with refractory angina showed durable improvements in exercise capacity, with fewer angina episodes over follow-up.
• The readout supports continued clinical development, positioning CardiAMP as a potential option for patients who have exhausted standard drug, catheter-based, or surgical treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210800PRIMZONEFULLFEED9724372) on May 21, 2026, and is solely responsible for the information contained therein.